AR065573A1 - Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start. - Google Patents

Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start.

Info

Publication number
AR065573A1
AR065573A1 ARP080100873A ARP080100873A AR065573A1 AR 065573 A1 AR065573 A1 AR 065573A1 AR P080100873 A ARP080100873 A AR P080100873A AR P080100873 A ARP080100873 A AR P080100873A AR 065573 A1 AR065573 A1 AR 065573A1
Authority
AR
Argentina
Prior art keywords
protein
pkd
cert
production
expression
Prior art date
Application number
ARP080100873A
Other languages
English (en)
Inventor
Monilola Olayioye
Lore Florin
Eric Becker
Hitto Kausmann
Angelika Hausser
Tim Fugmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07103406A external-priority patent/EP1964922A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR065573A1 publication Critical patent/AR065573A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)

Abstract

Método para la produccion de proteína y a la tecnología de cultivo celular. Se identifica la CERT (proteína de transferencia de ceramida) como un sustrato in vivo de proteína quinasa (PKD). La fosforilacion en la serina 132 por PKD reduce laafinidad de CERT hacia su diana lipídica 4-fosfato de fosfatidilinosiol en las membranas de Golgi y reduce la actividad de transferencia de ceramida, identificando a PKD como un regulador de la homeostasis lipídica. La CERT es a su vez crítica paraal activacion de PKD y el transporte de carga de proteína dependiente de PKD a la membrana plasmática. La interdependencia de PKD y CERT es por tanto clave para el mantenimiento de la integridad de la membrana de Golgi y el transporte secretor.Vector de expresion, célula que lo comprende, composicion farmacéutica, y usos de la proteína con dominio START.
ARP080100873A 2007-03-02 2008-02-29 Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start. AR065573A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07103406A EP1964922A1 (en) 2007-03-02 2007-03-02 Improvement of protein production
EP07104226 2007-03-15
EP07116358 2007-09-13

Publications (1)

Publication Number Publication Date
AR065573A1 true AR065573A1 (es) 2009-06-17

Family

ID=39639553

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080100873A AR065573A1 (es) 2007-03-02 2008-02-29 Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start.
ARP120101384A Pending AR086476A2 (es) 2007-03-02 2012-04-20 Metodos de produccion de una proteina de interes heterologa en una celula, para aumentar la productividad celular especifica de una proteina de interes de membrana o secretada en una celula, para aumentar la eficacia de transfeccion de una celula que expresa una proteina de interes de membrana o secretada en una celula y para identificar un modulador de la funcion de proteina con dominio start, vectores de expresion, celulas, proteinas, composiciones farmaceuticas y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP120101384A Pending AR086476A2 (es) 2007-03-02 2012-04-20 Metodos de produccion de una proteina de interes heterologa en una celula, para aumentar la productividad celular especifica de una proteina de interes de membrana o secretada en una celula, para aumentar la eficacia de transfeccion de una celula que expresa una proteina de interes de membrana o secretada en una celula y para identificar un modulador de la funcion de proteina con dominio start, vectores de expresion, celulas, proteinas, composiciones farmaceuticas y sus usos

Country Status (24)

Country Link
US (4) US8221999B2 (es)
EP (3) EP2126093B1 (es)
JP (1) JP5467415B2 (es)
KR (1) KR20100015363A (es)
AR (2) AR065573A1 (es)
AU (1) AU2008223874B2 (es)
BR (1) BRPI0808542A2 (es)
CA (1) CA2677925A1 (es)
CY (1) CY1113710T1 (es)
DK (1) DK2126093T3 (es)
EA (1) EA018190B1 (es)
ES (1) ES2397274T3 (es)
HK (1) HK1136314A1 (es)
HR (1) HRP20121077T1 (es)
IL (1) IL200030A0 (es)
MX (1) MX2009009156A (es)
MY (1) MY148472A (es)
NZ (1) NZ580043A (es)
PL (1) PL2126093T3 (es)
PT (1) PT2126093E (es)
SG (1) SG182160A1 (es)
SI (1) SI2126093T1 (es)
TW (1) TWI419902B (es)
WO (1) WO2008107388A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182160A1 (en) 2007-03-02 2012-07-30 Boehringer Ingelheim Pharma Improvement of protein production
US8597909B2 (en) * 2008-09-10 2013-12-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of HSA-producing cells
KR20120014899A (ko) * 2009-05-05 2012-02-20 베링거 인겔하임 인터내셔날 게엠베하 Ｃｈｏ／ｃｅｒｔ 세포주
JP2012526536A (ja) * 2009-05-15 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンビナトリアルエンジニアリング
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
FI3378535T3 (fi) 2011-10-28 2023-04-12 Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
HUE059110T2 (hu) 2011-12-16 2022-10-28 Modernatx Inc Módosított MRNS készítmények
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
KR101438533B1 (ko) * 2012-03-30 2014-09-17 한양대학교 산학협력단 적혈구계 세포의 인 비트로 확장방법
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF PROTEINS
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US8886625B1 (en) 2012-10-31 2014-11-11 Google Inc. Methods and computer-readable media for providing recommended entities based on a user's social graph
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US8972368B1 (en) * 2012-12-07 2015-03-03 Google Inc. Systems, methods, and computer-readable media for providing search results having contacts from a user's social graph
CN105121465B (zh) 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP2017512772A (ja) 2014-03-12 2017-05-25 プロセナ バイオサイエンシーズ リミテッド Ｌｇ１〜３に特異的な抗ラミニン４抗体
ES2744526T3 (es) 2014-03-12 2020-02-25 Prothena Biosciences Ltd Anticuerpos anti-MCAM y métodos de uso asociados
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) * 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
JP2018530540A (ja) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
UA124148C2 (uk) 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
SG10202110774QA (en) 2017-03-29 2021-11-29 Boehringer Ingelheim Rcv Gmbh Recombinant host cell with altered membrane lipid composition
IL270375B2 (en) 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
AU2018345807B2 (en) 2017-10-06 2025-02-06 Novo Nordisk A/S Methods of detecting transthyretin
SG11202001127TA (en) * 2017-10-16 2020-03-30 Regeneron Pharma In situ raman spectroscopy systems and methods for controlling process variables in cell cultures
WO2020112687A2 (en) 2018-11-26 2020-06-04 Forty Seven, Inc. Humanized antibodies against c-kit
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
CN110592044B (zh) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 蛋白激酶Fused编码基因及其在防治小菜蛾中的应用
CN111100865B (zh) * 2020-01-07 2022-03-18 江南大学 一种提高酿酒酵母丁醇耐受能力的方法
BR112022026508A2 (pt) 2020-06-24 2023-03-07 Prothena Biosciences Ltd Anticorpos que reconhecem sortilina

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
US6579969B1 (en) * 1999-02-24 2003-06-17 Juan Saus Goodpasture antigen binding protein
EP1514933A1 (en) * 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
WO2002097044A2 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7326768B2 (en) * 2003-02-05 2008-02-05 Juan Saus Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
EP1639095A2 (en) 2003-06-11 2006-03-29 Biogen Idec MA Inc. Method to increase protein production in culture
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
JP2005035926A (ja) 2003-07-14 2005-02-10 Japan Science & Technology Agency セラミド輸送を促進する薬剤、該薬剤を製造する塩基配列、セラミド遊離を促進する活性の測定方法、及びセラミドの膜間移動を促進する活性の測定方法
WO2005116204A1 (ja) 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
BRPI0622254A2 (pt) 2005-06-20 2011-08-09 Genentech Inc anticorpo isolado, conjugado de droga e anticorpo, formulação farmacêutica, método de inibição da proliferação celular, método de tratamento de cáncer, teste de detecção de células cancerosas, artigo industrializado, uso de um composto conjugado de droga e anticorpo e uso de uma formulação farmacêutica
SG182160A1 (en) * 2007-03-02 2012-07-30 Boehringer Ingelheim Pharma Improvement of protein production
US20090018099A1 (en) 2007-03-02 2009-01-15 Hitto Kaufmann Protein production
KR20120014899A (ko) 2009-05-05 2012-02-20 베링거 인겔하임 인터내셔날 게엠베하 Ｃｈｏ／ｃｅｒｔ 세포주

Also Published As

Publication number Publication date
US20130177919A1 (en) 2013-07-11
TWI419902B (zh) 2013-12-21
PT2126093E (pt) 2012-12-03
JP2010519917A (ja) 2010-06-10
EP2126093A1 (en) 2009-12-02
AU2008223874B2 (en) 2014-06-26
EA200901168A1 (ru) 2010-06-30
JP5467415B2 (ja) 2014-04-09
ES2397274T3 (es) 2013-03-05
NZ580043A (en) 2012-04-27
AR086476A2 (es) 2013-12-18
MY148472A (en) 2013-04-30
EA018190B1 (ru) 2013-06-28
US8221999B2 (en) 2012-07-17
US20130196430A1 (en) 2013-08-01
DK2126093T3 (da) 2013-01-07
US20130197196A1 (en) 2013-08-01
EP2126093B1 (en) 2012-10-10
KR20100015363A (ko) 2010-02-12
HK1136314A1 (en) 2010-06-25
WO2008107388A1 (en) 2008-09-12
MX2009009156A (es) 2009-09-04
AU2008223874A1 (en) 2008-09-12
CA2677925A1 (en) 2008-09-12
HRP20121077T1 (hr) 2013-01-31
BRPI0808542A2 (pt) 2014-08-26
SI2126093T1 (sl) 2013-01-31
PL2126093T3 (pl) 2013-03-29
CY1113710T1 (el) 2016-06-22
EP2522729A1 (en) 2012-11-14
TW200846368A (en) 2008-12-01
US20080300207A1 (en) 2008-12-04
IL200030A0 (en) 2011-08-01
SG182160A1 (en) 2012-07-30
EP2522730A1 (en) 2012-11-14

Similar Documents

Publication Publication Date Title
AR065573A1 (es) Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start.
Zhang et al. Mitochondrial cAMP signaling
Kondo et al. Physiological unfolded protein response regulated by OASIS family members, transmembrane bZIP transcription factors
Lee et al. Mitochondrial membrane dynamics—functional positioning of OPA1
Itzstein et al. The regulation of osteoclast function and bone resorption by small GTPases
Tagaya et al. Regulation of mitochondrial dynamics and autophagy by the mitochondria-associated membrane
Funakoshi et al. Regulation of PIP5K activity by Arf6 and its physiological significance
De Matteis et al. Endoplasmic reticulum–Golgi complex membrane contact sites
CR10756A (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
Chojnacka et al. Cox17 protein is an auxiliary factor involved in the control of the mitochondrial contact site and cristae organizing system
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
AR060841A1 (es) Produccion de etanol en hospedantes no recombinantes
BRPI0911385A2 (pt) mutantes fgf21 e seus usos
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
BR112021025130A2 (pt) Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos
BR112019004010A2 (pt) fator de transcrição nterf241 e métodos de uso do mesmo
BR112014018610A2 (pt) alfa-amilase
ES2560430T3 (es) Sistema de expresión en levadura para la producción de moléculas aromáticas
BR112014032567A2 (pt) purificação de iduronato-2-sulfatase
BR112016025898A2 (pt) ?drimenol sintases e método para produzir drimenol?
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
Hickey et al. Proteins associated with immunopurified granules from a model pancreatic islet β-cell system: proteomic snapshot of an endocrine secretory granule
BR112014018534A8 (pt) método para a fabricação de uma proteína, microrganismo e uso de um microrganismo
BR112022001963A2 (pt) Fator de transcrição nterf221 e métodos de uso do mesmo
Adhikari et al. Neuronal ceroid lipofuscinosis related ER membrane protein CLN8 regulates PP2A activity and ceramide levels

Legal Events

Date Code Title Description
FC Refusal